Menu Search
Equities

DMS Imaging SA

ALIMG:BRU

DMS Imaging SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)0.024
  • Today's Change0.00 / 0.00%
  • Shares traded132.73k
  • 1 Year change+14.29%
  • Beta0.6656
Data delayed at least 15 minutes, as of May 02 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

DMS Imaging SA, formerly known as Asit Biotech SA is a France-based high-tech company. The Company is based in the south of France specialized in medical imaging diagnostics. It’s brands include Apelem, DMS, AXS Medical and Medilink, which offer a range of solutions in radiology, bone densitometry, stereo-radiography and post urology, all of which are adapted to the demands of the global marketplace. The Company serves across 140 countries through it’s subsidiaries and joint-ventures. It generates maximum of the turnover through the exportation market.

  • Revenue in EUR (TTM)40.56m
  • Net income in EUR-709.00k
  • Incorporated1997
  • Employees124.00
More ▼

Institutional shareholders

0.02%Per cent of shares held by top holders
HolderShares% Held
Lemanik Asset Management SAas of 30 Jun 2023241.80k0.02%
Data from 29 Feb 2024 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.